Emgality® (galcanezumab-gnlm), by Eli Lilly and Company


Physician Resources
1 FILES

Patient Resources
1 FILES

Patient Resources
Savings and Support
2 FILES

Savings & Support
Indications & Usage

INDICATIONS AND USAGE

EMGALITY® is a calcitonin-gene related peptide antagonist indicated in adults for the:

·         preventive treatment of migraine.

·         treatment of episodic cluster headache. 


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Dosage & Administration

DOSAGE AND ADMINISTRATION

·         For subcutaneous use only.  

·         Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg.

·         Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period.

·         Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. 


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Dosage Forms and Strengths

DOSAGE FORMS AND STRENGTHS


·         Injection: 120 mg/mL solution in a single-dose prefilled pen

·         Injection: 120 mg/mL solution in a single-dose prefilled syringe

·         Injection: 100 mg/mL solution in a single-dose prefilled syringe


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Contraindications

CONTRAINDICATIONS

EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. 


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Warnings & Precautions

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration, and may be prolonged.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Adverse Reactions

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


PP-GZ-US-1385 10/2020 © Lilly USA, LLC 2020. All rights reserved. 

Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.



Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

IMPORTANT SAFETY INFORMATION


Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

 

Warnings and Precautions

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

 

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions. 


GZ HCP ISI 10DEC2019


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.